World Health Organisation Temporarily Suspends Clinical Trials Of Hydroxychloroquine
Director-General Dr. Tedros has said that WHO is putting its solidarity trail on HCQ and chloroquine on temporary pause to review benefits and harms.
The World Health Organisation (WHO) suspends the trial of Hydroxychloroquine (HCQ) as a potential treatment for COVID-19. However, the suspension is temporary in nature. With respect to safety concerns, last week, a study indicated that using HCQ on coronavirus patients could increase their likelihood of dying. WHO said its “Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the solidarity trial while the data is reviewed by the Data Safety Monitoring Board.”
WHO Chief Tedros said, “On Friday, the Lancet has published an observational study on hydroxychloroquine and chloroquine, and its effects on COVID-19 patients that have been hospitalised.” The authors reported that among the patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.
— World Health Organization (WHO) (@WHO) May 25, 2020
US President Trump has repeatedly said that prescribing this anti-malarial drug could combat coronavirus. The US Food and Drug Administration had earlier warned of potential side effects of the drug if used on COVID-19 patients.
Get more news updates only on ZEE5.